Recently, Li et al.14 reported that TOPK silencing inhibited the growth and enhanced the gefitinib sensitivity of lung cancer cells, and TOPK is considered a potential therapeutic target and a prognostic marker for lung cancer. Here, PBK is linked to lung carcinoma.